Today: 11 June 2026
Citigroup Stock (C) After Hours on Dec. 12, 2025: JPMorgan Upgrade, Banamex Watch, and What to Know Before the Next Market Open
13 December 2025
6 mins read

Citigroup Stock (C) After Hours on Dec. 12, 2025: JPMorgan Upgrade, Banamex Watch, and What to Know Before the Next Market Open

Citigroup, Inc. (NYSE: C) ended the Friday, December 12, 2025 session close to flat—then stayed calm after the bell—despite a high-profile analyst upgrade that helped put the bank back in the spotlight. The setup heading into the next trading session is less about a single headline and more about whether Citi’s 2025 rerating can keep going as Wall Street weighs: (1) the turnaround under CEO Jane Fraser, (2) regulatory and capital tailwinds for big banks, and (3) progress on the long-running Banamex plan in Mexico.

Below is what moved Citi on 12/12, what the after-hours tape said, and what to track before the market opens again.


Citigroup stock price action after the bell (12/12/2025)

Citigroup shares finished regular trading on Dec. 12 at about $111.80 (roughly +0.05% on the day), after opening near $113.30 and trading in a $113.43–$111.19 range. Volume was about 11.19 million shares.

In after-hours trading, quotes were essentially unchanged, hovering around $111.82–$111.92 later in the evening—suggesting no major new company-specific catalyst hit the tape after 4 p.m. ET.

Interpretation (not a prediction): the market appeared to absorb the day’s bullish research while broader risk-off crosscurrents (especially in tech) pulled attention elsewhere by the close.


The big 12/12 catalyst: JPMorgan upgrades Citigroup to “overweight”

The headline event for Citi on Dec. 12 was a J.P. Morgan upgrade to “overweight” from “neutral”, framed as a confidence vote in Citi’s multi-year turnaround and a belief that a mix of internal fixes and a supportive operating backdrop can finally translate into better profitability. Reuters

Reuters reported the upgrade leaned on themes Citi investors have been tracking for months:

  • Simplification and restructuring under CEO Jane Fraser
  • Stronger risk controls and investments in core businesses
  • A view that profitability improvement is the key driver for additional upside

Valuation: still discounted vs. peers, even after a huge 2025 run

One reason Citi keeps showing up in “turnaround + valuation” screens is that it has rallied hard and still looks cheaper than peers on some common yardsticks.

Reuters cited Citi at about 11.2x expected earnings over the next 12 months, versus about 15.04x for JPMorgan and 12.5x for Bank of America (LSEG data).

And despite the rally, Reuters noted Citi’s price-to-book remains well below peers—another way of saying the market still isn’t fully pricing Citi like a “finished” turnaround. Reuters

“Welcome to the club”: Citi’s bull case is getting less lonely

A colorful moment from the Reuters piece: Wells Fargo analyst Mike Mayo reacted to the JPMorgan upgrade with “Welcome to the club,” and reiterated Citi as a top pick for 2025 and 2026. Reuters

That matters because upgrades can be less about one bank’s model and more about the psychology of “permission” on the Street—especially when a turnaround name starts working and other firms don’t want to be late.


Price targets and forecasts updated on 12/12: what they imply

A key part of the 12/12 narrative was not just “upgrade” but also where analysts think the stock can go.

  • Multiple market summaries reported J.P. Morgan’s price target as $124 (up from $107).
    • From a ~$111.80 close, $124 implies roughly ~11% upside (purely mathematical, not a guarantee).
  • MT Newswires/MarketScreener also surfaced RBC raising its Citi price target to $121 from $112 while keeping an Outperform stance.
    • $121 from ~$111.80 implies roughly ~8% upside.
  • MarketScreener’s displayed consensus snapshot showed an average target near $115.57 (about +3.37% above the close) with a “BUY” consensus. MarketScreener

Why targets matter before the next open: after a year like Citi’s 2025 surge (~+59% YTD), the market often becomes hypersensitive to whether targets are chasing price or leading it. Reuters flagged Citi’s ~59% 2025 gain and its strong rank within financials.


Citi in the bigger bank-stock story on 12/12: regulation, consolidation, and “range breakout” talk

Barron’s put Citi in a broader frame: Bank of America hit a record close on Dec. 12, and Citi—benefiting from the same “friendlier Washington” narrative—reached its highest level since 2008, though it’s still been stuck in a long multi-decade trading range relative to its historic peak. Barron’s

Reuters also noted JPMorgan’s view that U.S. banks could benefit in 2026 from a solid economy, strong markets, and a favorable regulatory environment—plus ongoing industry consolidation (more deals).

This is crucial context for Citi specifically because:

  • Citi has meaningful markets and investment banking exposure (often helped by active capital markets),
  • Citi’s turnaround includes operational and control upgrades that investors hope will unlock capital return flexibility later, and
  • M&A optimism can lift the whole sector’s mood—even if Citi isn’t the acquirer.

Another Citi-specific storyline in the background: Banamex approval chatter

While the analyst upgrade dominated the day, another Citi catalyst has been simmering: the path toward Banamex (Citi’s Mexico retail banking unit) milestones.

A Bloomberg-sourced report carried by LiveMint said Mexican financial authorities were close to approving billionaire Fernando Chico Pardo’s offer to buy a 25% stake in Banamex—an approval step that could help clear the runway toward a future listing timeline. The same report cited Citi CFO Mark Mason suggesting he could “envision” the closing happening sooner than previously expected. mint

For context, Citi’s own September 2025 announcement described the planned 25% stake purchase, including the transaction structure and that it was subject to regulatory approvals in Mexico.

Why this matters for the stock: Banamex has been a long-running “value unlock / simplification” piece of Citi’s story. Any concrete progress tends to reinforce the simplification narrative that also sits at the heart of the JPMorgan upgrade.


Macro tape on 12/12: markets sold off in tech, not in banks

Even if Citi had company-specific tailwinds, the broader market mood matters for “after the bell” behavior.

On Dec. 12, U.S. equities had a rough day largely driven by tech/AI-related weakness (Broadcom’s drop was widely cited), with the Nasdaq down notably and the S&P 500 also lower.

Why a Citi investor cares: when markets rotate out of high-multiple growth, money often looks for:

  • value,
  • dividends,
  • cyclicals (including banks),
  • and “policy beneficiaries.”

That doesn’t mean banks rise every time tech falls—but it’s part of the sector chessboard that helps explain why Citi can be “up on upgrade” early and still finish near flat by the close.


What to know before the “market open” on 13/12/2025 (important calendar reality)

Here’s the small but important wrinkle: December 13, 2025 is a Saturday. The NYSE’s core trading session runs 9:30 a.m. to 4:00 p.m. ET on trading days, so there is no regular U.S. stock market open on Saturday.

So practically, what you’re really preparing for is the next trading session (the next U.S. market day after Friday), and what could change sentiment between Friday’s close and the next open.

The weekend / next-open checklist for Citigroup (C)

1) Any follow-through on the upgrade cycle
Upgrades often trigger a second wave: other firms publish notes, targets shift, and financial media recirculates the narrative. The key is whether Citi gets additional “me too” upgrades or whether Friday was the peak attention moment. Reuters+1

2) Mexico / Banamex headlines
If more outlets confirm regulatory progress—or push back on it—Citi can react because Banamex is still a high-signal simplification story.

3) Watch rates and yields (banks live and die by the curve)
Even without a Citi-specific headline, bank stocks can gap on moves in Treasury yields or shifting expectations around the pace of rate cuts/hikes. (Friday’s broad-market coverage emphasized rate and yield dynamics alongside the tech selloff.)

4) Confirm there was no late corporate filing
As of Citi’s investor relations SEC filings list, the most recent entry visible was an 8-K dated Dec. 10, 2025—nothing newly posted for Dec. 12 in that list.
That’s consistent with the quiet after-hours action: no surprise filing, no earnings release, no sudden strategic pivot.

5) Know the next scheduled major catalyst: earnings date is set
Citi has publicly posted its Q4 2025 earnings timing: results are slated for Wednesday, January 14, 2026 (about a month away), with the related call later that morning.

6) Keep an eye on the operating backdrop Citi itself has highlighted
Earlier in the week, Citi CFO Mark Mason said he expected Q4 investment banking fees up in the mid‑20% range year-over-year, while markets revenue was expected down low-to-mid single digits, and he discussed progress on reducing transformation expenses and the regulatory-capital conversation. Reuters
That’s not a 12/12 headline, but it’s part of the “why JPM upgraded” foundation.


Bottom line: what Friday night’s tape suggests

Citi (C) didn’t deliver fireworks after the bell on Dec. 12—it delivered something arguably more interesting: stability.

  • The stock tested higher intraday but closed near flat, and after-hours pricing stayed near the close.
  • The day’s key development was not a new Citi filing or surprise financial update, but a reframing of the turnaround by a major Wall Street firm, plus fresh price target resets.
  • Going into the next market open, the biggest swing factors are: follow-through analyst action, Banamex approval headlines, and macro (rates/yields + risk appetite).

Stock Market Today

  • Soybeans Trade Mixed Early Thursday as USDA Export Sales Awaited
    June 11, 2026, 10:49 AM EDT. Soybeans showed mixed trading early Thursday with futures down 1¼ to 1½ cents after Wednesday's gains of 4 to 9¼ cents. The national average Cash Bean price rose 10½ cents to $10.68½. Soymeal futures fluctuated, while Soy Oil futures increased by 33 to 55 points. The USDA is set to release weekly Export Sales data, with estimates for 2025/26 bean sales ranging between 150,000 and 400,000 metric tons (MT). Analysts expect steady carryout and new crop estimates in the upcoming WASDE report. Brazilian and Argentine production forecasts remain mostly stable, with slight revisions to crop sizes. Market watchers await these data points for clues on global supply and demand trends impacting soybean prices.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
CoreWeave (CRWV) Stock After the Bell on Dec. 12, 2025: Why Shares Sank and What to Know Before the Next Market Open
Previous Story

CoreWeave (CRWV) Stock After the Bell on Dec. 12, 2025: Why Shares Sank and What to Know Before the Next Market Open

DBS Stock Forecast 2026: Dividend, S$8B Capital Return Plan, and Analyst Targets as Shares Trade Near S$55
Next Story

DBS Stock Forecast 2026: Dividend, S$8B Capital Return Plan, and Analyst Targets as Shares Trade Near S$55

Go toTop